Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Lilly's Abemaciclib Overcome Third Place Finish In CDK4/6 Race?

Executive Summary

Lilly reported positive top-line results for abemaciclib in the Phase III MONARCH 2 trial and revealed a regulatory strategy that has it rapidly racing after competing CDK4/6 inhibitors already approved for certain breast cancer patients.

You may also be interested in...



Lilly Plumbs Data's Depths To Differentiate CDK4/6 Inhibitor Verzenio

Lilly highlighted five prognostic factors at SABCS that may be linked to high Verzenio response. As the third CDK4/6 inhibitor on the US market, the company needs to differentiate its breast cancer drug from Pfizer's Ibrance and Novartis's Kisqali.

Lilly Math: Subtracting Employees And Animal Health Equals Pharma Growth

Lilly is cutting 3,500 jobs and may spin out or divest its animal health business to support pharma growth as sales of new medicines contributed significant revenue in the third quarter, but price increases were needed to offset falling demand for mature products.

Lilly Hopes To Revitalize Its Cancer Brand With 'Foundational' Agents

While reporting 19% US sales growth for the quarter, Lilly also outlined a revised oncology R&D strategy and revealed that refiling the NDA for baricitinib may be delayed 18 months or more.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142209

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel